Atlas FDA

Oncomine Dx Target Test

FDA premarket approval P160045/S045 · decided 2024-06-17

Approval details

PMA number
P160045
Supplement
S045
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
Oncomine Dx Target Test
Generic name
Next generation sequencing oncology panel, somatic or germline variant detection system
Applicant
Life Technologies Corporation
Date received
2023-12-20
Decision date
2024-06-17
Days to decision
180 days
Decision code
APPR
Product code
PQP
Advisory committee
Pathology
Expedited review
No
Location
Carlsbad, CA
Statement
Approval to update the user guide and promotional materials for the Oncomine Dx Target Test to include the results of the study data as recommended by FDA in P160045/R011, P160045/R017, P160045/R018, P160045/R025, P160045/R028, P160045/R030, and P160045/R031.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel (K241806)Life Technologies Corporation2025-01-08
Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit (K233453)Life Technologies Corporation2024-07-10
Applied Biosystems™ 3500 Dx Genetic Analyzer and Applied Biosystems™ 3500xL Dx Genetic Analyzer (K191030)Life Technologies Corporation2020-02-21
Ion PGM Dx System (K170299)Life Technologies Corporation2017-06-22
QUANTSTUDIO DX REAL-TIME PCR INSTRUMENT (K123955)Life Technologies Corporation2013-03-08
STEMPRO MSC SFM (K103302)Life Technologies Corporation2011-02-18
KNOCKOUT SR MEDIUM, KNOCKOUT SR XENOFREE MEDIUM MODEL 10828, 12618 (K100616)Life Technologies Corporation2010-05-20